KWM
APYX icon

Kingsview Wealth Management’s Apyx Medical APYX Stock Holding History

Kingsview Wealth Management’s Portfolio APYX Stock Details APYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$962K Buy
214,288
+5,500
+3% +$21.8K 0.01% 760
2026
Q1 		$770K Buy
208,788
+20,595
+11% +$77K 0.01% 754
2025
Q4 		$659K Sell
188,193
-4,850
-3% -$16.9K 0.01% 759
2025
Q3 		$413K Buy
193,043
+1,446
+0.8% +$3.06K 0.01% 867
2025
Q2 		$431K Buy
191,597
+16,502
+9% +$23.2K 0.01% 823
2025
Q1 		$240K Buy
175,095
+39,850
+29% +$54.9K ﹤0.01% 979
2024
Q4 		$214K Buy
135,245
+10,800
+9% +$15.1K ﹤0.01% 1035
2024
Q3 		$154K Buy
124,445
+93,417
+301% +$118K ﹤0.01% 1052
2024
Q2 		$41.6K Hold
31,028
– – ﹤0.01% 1026
2024
Q1 		$42.2K Buy
31,028
+18,943
+157% +$40.3K ﹤0.01% 1003
2023
Q4 		$31.7K Buy
+12,085
New +$29.3K ﹤0.01% 934
2023
Q3 		– Sell
-10,017
Closed -$50.4K – 929
2023
Q2 		$50.4K Sell
10,017
-800
-7% -$4.05K ﹤0.01% 894
2023
Q1 		$31.2K Buy
+10,817
New +$31.6K ﹤0.01% 873

Other funds holding APYX

RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
ACM
Archon Capital Management Seattle, Washington $246M AUM 130.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EIM
Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SBCM
Silverberg Bernstein Capital Management Armonk, New York $261M AUM 89.93% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
HKAM
Horizon Kinetics Asset Management New York $8.82B AUM 23.05% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kingsview Wealth Management's APYX Position: Q2 2026 in Review

Kingsview Wealth Management increased its Apyx Medical (APYX) stake by 2.6% in Q2 2026, buying an estimated $21.8K and bringing the position to 214,288 shares worth $962K. The position accounts for 0.01% of the portfolio, ranked #760.

Kingsview Wealth Management first reported a position in APYX in Q1 2023 and has held it in 13 quarters since. 68 funds tracked by Wall St. Rank hold APYX as of Q2 2026.

  • Kingsview Wealth Management held 214,288 shares of Apyx Medical worth $962K as of Q2 2026.
  • Kingsview Wealth Management bought 5,500 Apyx Medical shares in Q2 2026, an estimated $21.8K.
  • Apyx Medical made up 0.01% of Kingsview Wealth Management's portfolio in Q2 2026, its #760 holding.
  • Kingsview Wealth Management first reported a position in Apyx Medical in Q1 2023 and has held it in 13 quarters since.
  • 68 funds tracked by Wall St. Rank held Apyx Medical as of Q2 2026.

Based on Kingsview Wealth Management's 13F filing for Q2 2026, filed 19 Aug 2026.